I. INTRODUCTION
Advances in proteomic concepts and technologies, particularly unbiased techniques, have stimulated a great interest in application of mass spectrometry (MS) to explore neurodegenerative disorders, for example, Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS)-one of the most important groups of diseases in our rapidly aging population in developing and industrialized countries (Chiang, Lam, & Luo, 2008) . Application of these techniques to neurodegenerative disorders is especially advantageous because, despite decades of ''mechanism''-or ''pathway'' -based pursuits, the pathogenesis of most of these diseases remains largely unknown (Cookson, 2005; Moore et al., 2005; Thomas & Beal, 2007; Arakawa, Kita, & Niikura, 2008; Siddique & Siddique, 2008) . Indeed, in the past several years, proteomic investigations that use different platforms with samples collected from AD and PD patients have already revealed quite a few novel proteins that are potentially critical, not only to the understanding of the mechanisms of the diseases but also to new avenues to diagnose these diseases and to monitor disease progression (Castegna et al., 2002; Butterfield et al., 2003; Jin et al., 2006; Finehout et al., 2007; Leverenz et al., 2007; Osorio et al., 2007; Simonsen et al., 2007) .
Defining protein biomarkers unique to a disease diagnosis or progression in body fluids, particularly cerebrospinal fluid (CSF), is currently one of the most exciting areas of research in neurodegenerative disorders (Yuan & Desiderio, 2003 Rite et al., 2007; Simonsen et al., 2007; Tumani et al., 2008; Yang et al., 2008) . CSF, which originates within the ventricles and surrounds the brain and spinal cord, is an ideal source for biomarker discovery for diseases of the central nervous system (CNS) like AD and PD. The reasons include (Abdi et al., 2006; Zhang, 2007; Srivastava, Murphy, & Jeffery, 2008) : (1) CSF is the only body fluid that directly interchanges with the extracellular fluid of the CNS, and therefore reflects pathological changes in the CNS most directly, and (2) multiple CSF taps can be obtained with minimal risk to make possible a longitudinal analysis of biomarkers in a given cohort. That said, among thousands of proteins identified by proteomics in human CSF thus far (Pan et al., 2007b; Zougman et al., 2008) , only a small portion are related to the CNS structurally or functionally. This deficit in identifying CNS-specific proteins is mainly due to the fact that most of the CNS-specific proteins are low in abundance, and all current proteomic techniques are biased towards abundant proteins in a sample with a large dynamic range (Gulcicek et al., 2005) . One of the approaches to get around this difficulty is to focus on a subproteome(s) that can be isolated readily (e.g., proteins with glycosylation, phosphorylation, or oxidation) before proteomic profiling, thereby effectively reducing the dynamic range of a given complex sample (Korolainen et al., 2002; Bahl et al., 2008; Kubota et al., 2008) . To this end, characterizing glycoproteins is especially appealing because they are intimately related to the health of cells, and in addition, are relatively enriched in body fluids like CSF and plasma (Ohtsubo & Marth, 2006) .
In this report, we will begin by summarizing the current understanding of glycoproteins in biology and neurodegenerative disease, followed by an introduction of existing proteomic technologies used to characterize glycoproteins. Next, we will present some of the ongoing studies where glycoproteins isolated from human CSF and brain tissue are characterized in PD at different stages and in controls. Future applications of targeted proteomics-to identify unique proteins in the CNS first, followed by confirmation/validation of known proteins in CSF or plasma-also will be addressed briefly.
II. GLYCOPROTEINS IN HEATH AND NEURODEGENERATIVE DISEASE

A. Glycosylation in Health and Disease
Post-translational modifications (PTMs) play a key role to modulate the activities and functions of most proteins in biological systems (Hann, 2006) . Among various PTMs, glycosylation represents the most common and complicated form. It is estimated that 50-60% of proteins in the human body are modified by glycosylation (Apweiler, Hermjakob, & Sharon, 1999; Hagglund et al., 2004; Kameyama et al., 2006) . A glycoprotein often contains more than one oligosaccharide attachment site, and each glycosylation site can be modified with multiple oligosaccharide chains. Additionally, on a single glycoprotein, the structure of oligosaccharides at each site can be significantly different. Various glycosylated proteins are synthesized mainly in the endoplasmic reticulum and Golgi via reactions that involve sugar nucleotide synthases, transporters, glycosyltransferases, glycosidases, and other sugar-modifying enzymes. In addition, the structures of glycans can be easily altered by changes of the physiological condition of the cells (Lowe & Marth, 2003; Haltiwanger & Lowe, 2004) . It should be noted that, although it is beyond a review focused on glycoproteins, a mass spectrometric study of glycans is itself an active area of current research (Morelle & Michalski, 2005; Zaia, 2008) .
The amino acids known to be involved in glycosylation are asparagine, arginine, serine, threonine, proline, hydroxyproline, tryptophan, and tyrosine (Spiro, 2002) . Typically, protein glycosylation is categorized as either O-linked or N-linked. The N-linked glycosylation, characterized by the attachment of the glycan to an asparagine side chain of the protein, is by far the most common (Nalivaeva & Turner, 2001 ). The consensus sequence for N-glycosylation is Asn-Xaa-Ser/Thr, where Xaa is any amino acid other than proline (Johansen, Marshall, & Neuberger, 1961) . The asparagine is linked to N-acetylglucosamine (GlcNAc) residues. Additional sugar residues in the glycan depend on whether the glycosylation is the high-mannose hybrid or complex type (Suzuki et al., 1995) . In O-linked glycosylation, on the other hand, the glycan is attached to the serine/threonine side chain (Spiro, 1973) . O-linked glycosylation usually starts with an N-acetylgalactosamine (GalNAc) linked to serine/threonine and, unlike N-linked glycosylation, no consensus sequence that defines an O-linked glycosylation site exists (Spiro, 1964 (Spiro, , 1973 (Spiro, , 2002 Tanaka, Bertolini, & Pigman, 1964) . This type of glycosylation is observed most abundantly in mucin-like glycoproteins that form part of epithelial secretions in, for example, the gut, cervix, and lungs (Gendler & Spicer, 1995; Hanisch, 2001) . Another variation of O-linked glycans is the Ser/Thr-O-GlcNAc sequence, which is abundant in nucleocytosolic proteins that aid in signal transduction (Spiro, 2002) .
One of the initial functions of glycosylation of a given protein is to direct the protein to the appropriate subcellular location; for example, many lysosomal proteins contain a mannose-6-phosphate moiety, a signaling molecule for lysosome (Kaplan, Achord, & Sly, 1977; Varki & Kornfeld, 1980) . Additionally, glycosylation has been implicated in numerous biological processes, including cell growth and developmental biology, immune response, tumor growth, metastasis, anticoagulation, cell-to-cell communication, and microbial pathogenesis (Liu et al., 2002; Sasisekharan et al., 2002; Hwang et al., 2003; Inatani et al., 2003; Lowe & Marth, 2003; Casu, Guerrini, & Torri, 2004; Collins & Paulson, 2004; Guo et al., 2004; Lin, 2004; Dube & Bertozzi, 2005; Kinjo et al., 2005; Miller, Ernst, & Bader, 2005) . Aberrant protein glycosylations could also contribute to human disorders, including neurodegenerative diseases (Liu et al., 2002; Saez-Valero et al., 2003) .
B. Glycosylation Alterations in Human Neurodegenerative Disorders
Alterations in protein glycosylation have been related to human neurodegenerative disease states, such as Creutzfeldt-Jakob disease (CJD), AD, and PD (Saez-Valero et al., 2003; Silveyra et al., 2006) . Although the structural elucidation of glycoproteins is a challenge because of their inherent complexity and heterogeneity in biological systems, advances have been made to identify a few proteins where glycosylation appears to be important in the disease processes of AD and PD (Sihlbom et al., 2004) . A few key proteins involved in AD and PD pathogenesis are discussed below.
Acetylcholinesterase (AChE), one of the critical enzymes targeted in the current clinical management of AD, hydrolyzes the neurotransmitter acetylcholine at cholinergic synapses, and is widely distributed in brain regions. The glycosylation of AChE is altered in the post-mortem brain and CSF of AD patients (SaezValero et al., 1999 (SaezValero et al., , 2000 . Additionally, the change in glycosylation of AChE appears to be specific for AD because it is not seen in other neurological diseases. More recently, the glycosylation of a related enzyme, butyrylcholinesterase (BuChE), also appears to be altered in AD CSF (Saez-Valero & Small, 2001) . Unfortunately, the sensitivity of diagnosing AD with AChE and BuChE in the CSF is lower than that considered necessary for a satisfactory biomarker (Saez-Valero et al., 2003) .
Microtubule-associated protein (MAP) tau, another essential protein involved in AD pathogenesis and related tauopathies, undergoes several PTMs, and aggregates into paired helical filaments. Known modifications of tau include hyperphosphorylation, glycosylation, ubiquitination, glycation, polyamination, nitration, and proteolysis. Glycosylation of tau is an early abnormality that might facilitate the hyperphosphorylation of tau, a pathological hallmark, in an AD brain (Liu et al., 2002) . Robertson, Moya, and Breen (2004) observed a significant decrease in the glycosylated tau (O-linked) in AD post-mortem brain samples compared with control; that decrease suggested an inverse relationship between the two PTMs (i.e., glycosylation vs. hyperphosphorylation). Furthermore, cells transfected with the cDNA coding for O-GlcNAc transferase displayed altered tau phosphorylation patterns as compared with control cells; these alterations again suggested that changes in tau glycosylation might influence its phosphorylation state. However, glycosylation of tau as a biomarker for AD has not been reported.
Until recently, very little has been known about the role of glycosylated proteins in PD. Farrer et al. (2001) noted a potential connection between the dysfunction of parkin, an E3 ubiquitin ligase involved in the ubiquitination of protein substrates that targets them for degradation by the proteasomal complex, and the formation of a-synuclein inclusions. It turned out that the mechanism that underlies this process could be the parkinmediated ubiquitination of an O-linked glycosylated form of asynuclein (Shimura et al., 2001) . It should be emphasized that mutations of parkin and a-synuclein result in the development of autosomal recessive and dominant familial PD, respectively (Tan & Skipper, 2007; Wakabayashi et al., 2007) , and that changes in the total amount of a-synuclein in CSF have been tested as potential biomarkers of PD (also see later discussion).
From what has been discussed above, it is obvious that glycosylation and glycoproteins play critical roles not only in normal physiological conditions but perhaps also in neurodegenerative disorders like in AD and PD. On the other hand, aside from two earlier reports of CSF glycoproteins (Sihlbom et al., 2004; Pan et al., 2006) , there is no systematic analysis of glycoproteins in human tissue or CSF for any disease or even in control subjects. Thus, in this report, we will present the glycoproteins identified in human brain in addition to CSF after an introduction of the current proteomic techniques used for characterization of glycoproteins.
III. CHARACTERIZATION OF GLYCOPROTEINS BY MASS SPECTROMETRY-BASED PROTEOMICS
A. Enrichment of Glycoproteins
As discussed above, the glycoproteome represents one of the most important sub-proteomes in tissues and body fluids. However, many glycoproteins might be low in abundance in their glycosylated forms, even though the parent proteins are abundant in CSF or plasma. Consequently, numerous attempts have been made to develop methods to enrich glycoproteins present in complex biological samples prior to mass spectrometric analysis.
Enrichment by Lectin Column
Lectins are widely distributed in nature and can recognize carbohydrates on the surface of proteins. To isolate glycoproteins or glycopeptides by affinity chromatography, various lectins can be used (Cummings & Kornfeld, 1982; Hirabayashi, 2004) . Concanavalin A (ConA) is a lectin that binds mannosyl and glucosyl residues that contain unmodified hydroxyl groups at positions C3, C4, and C6, and can be utilized for the targeted binding of certain oligosaccharide structures of N-glycosylated proteins (Goldstein, Hollerman, & Smith, 1965; Yahara & Edelman, 1972; Kamra & Gupta, 1987) . The use of wheat germ agglutinin (WGA) isolates glycostructures with N-acetylglucosamine and sialic acids (Nagata & Burger, 1974) . Arachis hypogaea agglutinin (PNA) is specific to glycans that contain b-Gal, whereas Datura stramonium agglutinin (DSA) is specific to glycans that contain GlcNAc residues (Novogrodsky et al., 1975; Yamashita et al., 1987) . Due to their ability to specifically recognize distinct oligosaccharide epitopes (Sharon & Lis, 1989) , lectins bound to appropriate matrices like agarose, membranes, or magnetic beads, can be used to isolate, fractionate, and characterize glycoproteins on the basis of their different glycan structures (Wiener & van Hoek, 1996; Bundy & Fenselau, 2001 ). In this regard, affinity chromatography with lectins is a useful and powerful technique to fractionate and isolate glycans and glycopeptides. The combination of lectin chromatography and MS analysis provides high-sensitive detection and useful information on glycan structures, and enables further biological approaches. However, because individual lectins display unique binding specificities, separation with a particular lectin will isolate only a fraction of glycoproteins or glycopeptides that bind to that lectin with high affinity (Xiong, Andrews, & Regnier, 2003; Bunkenborg et al., 2004; Ghosh et al., 2004) . To overcome the limitation of selective capture of a subset of glycoproteins for a given lectin, a technique has been introduced for glycoprotein/peptide isolation and enrichment from complex mixtures that involves double lectin chromatography prior to identification with liquid chromatograph (LC)-electrospray ionization (ESI) MS . Recently, a more elegant method has been established with a multi-lectin column, which allows for an almost complete enrichment of glycoproteins from biological fluids (Yang & Hancock, 2004; Wang, Wu, & Hancock, 2006) . In a similar manner, lectin arrays have been developed that contain more than 35 different lectins that allow a qualitative and quantitative profiling of glycoprotein glycan patterns in a rapid and sensitive high-throughput manner (Kuno et al., 2005) . Finally, lectin microcolumns have also been generated that are applicable to high-pressure analytical schemes, and thus, can be directly coupled on-line to ESI-MS to enable a highly sensitive semiautomated profiling of glycoproteins (Madera, Mechref, & Novotny, 2005; Madera et al., 2006 Madera et al., , 2007 .
Enrichment with Hydrazide
Hydrazide chemistry has been used to selectively isolate, identify, and quantify N-linked glycopeptides in a much more specific and efficient manner (Zhang et al., 2003) . This method is based on the conjugation of glycoproteins to a solid support with hydrazide chemistry after periodate-mediated oxidation of the carbohydrate. Peptide moieties of the covalently captured glycopeptides are released with PNGase F treatment to allow the peptide and glycosylation site to be identified. Recently, Sun et al. (2007) reported a novel chemical capture approach that focuses on a more efficient glycopeptide enrichment. In this approach, glycopeptides derived from glycoproteins are enriched by selective capture onto a solid support with hydrazide chemistry followed by enzymatic release of the peptides and subsequent analysis by tandem MS. Digestion of proteins into peptides improves the solubility of large membrane proteins, and exposes all of the glycosylation sites (at least in theory) to ensure an equal accessibility to external capture reagents. Notably, whereas the specificity has been increased by capturing N-linked glycopeptides/glycoproteins with the hydrazide chemistry, this method is restricted to N-glycopeptides and, in addition, information on the carbohydrate structures is lost due to the destruction and removal of the glycan moieties.
Other Methods for Enriching Glycoproteins
Besides lectins and hydrazide, a few other techniques, including treatment with boronic acids, have also been employed to facilitate enrichment of glycoproteins. Because boronic acids enhance the capture of the more heterogeneous group of O-linked oligosaccharides, this method has been incorporated into lectin methodology; for example, a boronic acid-lectin affinity chromatography column has been used to isolate glycoproteins with selective and/or combined elution (Monzo, Bonn, & Guttman, 2007) .
B. Mass Spectrometric Analysis of Glycoproteins/ Peptides
Modern MS has greatly facilitated the characterization of glycoproteins because it provides glycosylation site-specific information by conducting glycopeptide-based analysis, wherein the glycan and its attachment site to the protein can be elucidated in the same experiment; at least in theory. This glycosylation sitespecific information is useful to elucidate functional properties of the glycoprotein. Typically, glycopeptide-based MS analysis entails an enzymatic cleavage of glycoproteins with an endoprotease, followed by a separation technique and mass analysis.
Desalting
When analyzing glycopeptides and glycoproteins, it is necessary to desalt the sample and remove organic contaminants to avoid the formation of salt adducts, thereby obtaining more-informative MS spectra. Cation and anion exchange materials have been used commonly for desalting (Lattard et al., 2006) . One of the efficient methods is to use a microcolumn in a GELoader tip (Eppendorf) into which a mixed bed resin column of AG-3 (to remove anions), AG-50 (to remove cations), and C18 (to remove organic materials) are packed (Kussmann et al., 1997) . Hydrophilic interaction liquid chromatography (HILIC) (Hagglund et al., 2004) and graphite columns (Larsen, Cordwell, & Roepstorff, 2002) are also useful for desalting.
Identification of Glycoproteins by Mass Spectrometric Technologies
Most of the large-scale glycoprotein identification studies have used a shotgun proteomics approach, in which glycoproteins are typically trypsin-digested and de-glycosylated so that glycosylated peptides can be sequenced in their deglycosylated forms with MS/MS. For glycopeptides with N-linked glycosylation site(s), most of the glycans can be removed with PNGase F. The enzyme cleavage of a glycan group converts asparagine to aspartic acid in a peptide, to introduce a mass difference of 0.984 Da and a negative charge. This phenomenon was used to map the N-linked glycosylation site(s) using MS (Zhou, Aebersold, & Zhang, 2007) . In the past few years, several studies have used MS to profile N-linked glycoproteins in human body fluids. Liu et al. (2005) applied immunoaffinity subtraction and hydrazide chemistry to enrich glycoproteins from human plasma. The captured plasma glycoproteins were subjected to two-dimensional (2D) LC separation (strong cation exchange [SCX] and reverse-phase capillary LC) followed by tandem MS or MS/MS analysis with a Fourier transform ion cyclotron resonance mass spectrometer. A detection sensitivity at low ng/mL was achieved. A total of 2,053 different N-glycopeptides, representing 303 nonredundant glycoproteins, were identified, including many lowabundance glycoproteins. Other studies applied a lectin affinitybased approach to characterize serum and plasma N-linked glycoproteins, and have added significant numbers of glycoproteins to the blood glycoproteome database (Zhang et al., 2003; Yang & Hancock, 2004) . Related to the study of neurodegenerative diseases, the CSF glycoproteome has been investigated in an experiment, where lectin affinity and hydrazide chemistry enrichment methods were both applied to reveal 216 glycoproteins .
Different approaches have characterized O-glycosylation with tandem mass spectrometry. A very sensitive technique to identify O-glycosylated sites employs the use of ammonia or ethylamine for the specific release of O-linked glycan chains. The integrity of the peptide backbone was retained and ammonia or ethylamine was incorporated into the amino acid residue(s) to which the glycan(s) had been attached. Thus, the former glycosylation site was labeled, and thus, can be identified by the mass alteration of À1 Da and þ27 Da for ammonia and ethylamine, respectively (Rademaker et al., 1998; Hanisch, Jovanovic, & Peter-Katalinic, 2001 ). The limitations of collisioninduced dissociation (CID) ESI-MS/MS for glycosylation site analysis (i.e., the dominating fragmentation of the glycan chains) can be overcome with different tandem MS techniques. Haynes and Aebersold (2000) demonstrated a technique that provided simultaneous detection and identification of O-GlcNAc-modified peptides with low-energy collisions in tandem MS. The differential between the energy required to remove the O-GlcNAc group versus the energy required to fragment the peptide chain allows the O-GlcNAc group to be detected and the peptide sequence, and therefore the protein, to be identified. More recently, ''soft'' collision techniques, such as electron capture dissociation (ECD) and electron transfer dissociation (ETD) (Mormann, Paulsen, & Peter-Katalinic, 2005; Catalina et al., 2007) , have led to a preferential cleavage of the peptide backbone and to leaving glycan structures intact, to thus allow an unambiguous assignment of the glycosylation site in N-and Oglycopeptides (Hakansson et al., 2001; Hogan et al., 2005) . To enhance the specificity of O-glycosylation analysis, Durham et al. applied a serial lectin affinity chromatography that combine ConA and Jacalin to enhance the identification of O-glycosylated sites on proteins from the human blood proteome (Durham & Regnier, 2006) . The enriched O-glycopeptides were deglycosylated with oxidative elimination and analyzed with ESI and MALDI (matrix-assisted laser desorption/ionization) tandem MS to identify over thirty O-glycosylated glycoproteins from human serum.
MALDI-based mass spectrometric analysis usually produces singly charged glycopeptide ions that can be analyzed off-line with high sensitivity after deposition of nano-LC-derived glycopeptide fractions onto the MALDI-target (Lochnit & Geyer, 2004) . This technique is complementary to ESI technology, because ESI mass spectra are sometimes too complicated to fully assign oligosaccharide structures due to the formation of many multiply charged ions. With a MALDI-TOF/TOF-instrument, glycopeptides can be further analyzed via characteristic fragment ions that can sequence the glycan and the peptide simultaneously Kurogochi & Nishimura, 2004; Stephens et al., 2004; Wuhrer, Hokke, & Deelder, 2004) . Nonetheless, a more systematic assessment of O-or N-glycosylation sites on glycoproteins might require the use of mass spectrometers with higher mass accuracies; for example, ESI or MALDI with Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR) (Irungu et al., 2008) . FT-ICR MS provides the high mass accuracy needed to improve the specificity for protein database search results, and enhances the prediction of glycoforms. Sihlbom's group applied FT-ICR MS and infrared multi-photon dissociation (IRMPD) to determine the glycosylation states of isoforms of CSF proteins from individual AD patients compared to controls (Sihlbom et al., 2004) . In that study, they reported that the sub-femtomole sensitivities of FT-ICR MS analyzed 2D gel-separated complex human protein mixtures. An additional advantage to IRMPD is that it selectively dissociates the glycosidic bonds of N-linked glycans (amino acid consensus sequence N-X-S/T/C, in which X cannot be P).
Isotope Labeling for Quantification of Glycoproteins
Characterizing glycoproteins as extensively as possible is just the first step to define biomarkers unique to a disease or disease progression. A more important process is to quantify the changes associated with a disease or a disease stage. Additionally, quantitative glycoproteomics can help to characterize the regulatory pathways and complex system networks by providing protein concentration information that corresponds to different cellular states. Although label-free techniques have been developed by numerous investigators (Levin et al., 2007) , most published studies with human samples largely rely on various isotope-labeling techniques for quantification, particularly when large-scale profiling is the main focus. Examples include the use of chemical reactions to introduce isotopic tags at specific functional groups on peptides or proteins, such as ICAT (isotopecoded affinity tags) (Gygi et al., 1999; Haqqani, Kelly, & Stanimirovic, 2008) and iTRAQ (isobaric tags for relative and absolute quantitation) (Aggarwal, Choe, & Lee, 2006) as well as the methods that introduce stable-isotope tags via enzymatic reaction, such as enzymatic 18 O incorporation (Kaji et al., 2003 (Kaji et al., , 2006 Zhang et al., 2003) .
ICAT labels the side chains of cysteinyl residues in two reduced protein samples with the isotopic light or heavy reagent, respectively, and generates the mass signatures that identify sample origin and serve as the basis for accurate quantification, to thus afford simultaneous comparison of two proteomes. However, ICAT selectively targets cysteine residues, and therefore approximately 3% of mammalian proteins that lack cysteine residues cannot be analyzed (Colangelo & Williams, 2006 ). In addition, some cysteines are blocked or are inaccessible to the labeling reagent. More recently, iTRAQ technology, which labels lysines and N-termini, has been used for quantitative proteomics in human body fluid and tissue (Martin et al., 2008; Song et al., 2008) . The iTRAQ technology has a significant advantage over other methods due to its capability to multiplex up to eight samples in a single experiment (D'Ascenzo, Choe, & Lee, 2008). Another positive aspect includes unbiased peptide labeling, because iTRAQ isobaric tags theoretically label lysine side groups and all free amino-terminal groups of the peptides present in a sample. The iTRAQ tags consist of a reporter group, a balance group, and a peptide reactive group that covalently binds to the peptides. The tandem mass spectra include contributions from each sample, and the individual contributions of each sample can be measured by the intensity of the reporter ion peaks. Moreover, a chemical approach for the N-glycosylation identification (i.e., hydrazide chemistry capture) can be incorporated with the iTRAQ quantification method because an iTRAQlabeled peptide is chemically stable in other buffer systems.
Notably, in addition to quantification, isotope-labeling methods might also increase the certainty of glycoproteome assignments and enable quantitative comparisons of glycosylated samples. For example, several groups have used isotope-coded glycosylation-site-specific tagging (IGOT) for the large-scale identification of N-glycosylated proteins from a complex biological sample (Kaji et al., 2003 (Kaji et al., , 2006 . The IGOT approach is based on the lectin column-mediated affinity capture of a set of glycopeptides generated by tryptic digestion of protein mixtures, followed by peptide-N-glycosidase-mediated incorporation of a stable isotope tag, 18 O, specifically into the N-glycosylation site. The 18 O-tagged peptides are identified with multi-dimensional LC-MS-based technology. The application of this method to characterize N-linked high-mannose and/or hybrid-type glycoproteins from an extract of Caenorhabditis elegans proteins identified 250 glycoproteins, including 83 putative transmembrane proteins, with the simultaneous determination of 400 unique N-glycosylation sites. A similar approach was later used to identify and quantify N-linked glycoproteins in serum (Zhang et al., 2003) . In this study, the N-linked glycopeptides were oxidized and captured directly on a hydrazide column; the quantitation was achieved by comparing two samples that were tagged differentially with 
IV. CHARACTERIZATION OF GLYCOPROTEINS ASSOCIATED WITH PARKINSON'S DISEASE AND DISEASE PROGRESSION
In the next few sections, we will use one of the ongoing projects focused on PD to illustrate a strategy that identifies and quantifies CNS-specific glycoproteins at the same time. However, only identification data will be shown in this report.
A. Parkinson's Disease and Its Progression
PD is traditionally considered a movement disorder that results from a relatively selective loss of neurons in the brainstem, including dopaminergic (DAergic) neurons in the substantia nigra pars compacta (SNpc), with subsequent loss of striatal dopamine and accompanied by the formation of intraneuronal inclusions called Lewy bodies that contain a-synuclein as one of the major proteins (Lowe, Graham, & Leigh, 1997; Jankovic, 2001 ). More recently, however, it has become increasingly clear that neurodegeneration in PD is widespread with associated presentation of multiple ''non-motor'' symptoms, including cognitive impairment, particularly as the disease advances. Cognitive impairment in PD, ranging from mild dysfunction to severe dementia, has major clinical consequences, because it has been associated with a reduced quality of life (Schrag, Jahanshahi, & Quinn, 2000) , shortened survival (Nussbaum et al., 1998) , and increased caregiver distress compared to PD without cognitive impairment (Aarsland et al., 1999) . It should be emphasized that the risk of developing dementia in PD patients is several-fold higher than for community-dwelling controls (Marder et al., 1995; Aarsland et al., 2001 Aarsland et al., , 2003 . Furthermore, in more recent studies, when PD patients are tested more rigorously, it has been estimated that 36% of patients newly diagnosed with PD had mild cognitive impairment (MCI)-a prodrome of PD dementia (Foltynie et al., 2004; Levin & Katzen, 2005) , and that 57% of patients with newly diagnosed PD will develop MCI within 3-5 years (Williams-Gray et al., 2007) .
Numerous clinicopathological studies have sought to identify the structural basis of cognitive impairment in patients with PD dementia (PDD). Though remaining to be investigated, it appears that, in a significant portion of PD patients, PD progression is characterized pathologically by the spreading of aggregated a-synuclein deposits from the brainstem to other parts of the brain (Braak et al., 2002 (Braak et al., , 2003 . A staging procedure for the PD-related inclusion body pathology (i.e., Lewy neurites and Lewy bodies) in the brain proposes that the pathological process begins at two sites (the medulla oblongata and olfactory bulb) and progresses in a topographically predictable sequence in six stages. During stages 1-2, the inclusion body pathology remains confined to the medulla oblongata, pontine tegmentum, and anterior olfactory structures. In stages 3-4, the basal midbrain, including SNpc, and forebrain become the foci of the pathology, and the illness reaches its symptomatic phase (motor symptoms). In the final stages 5-6, the pathological process is seen in the association areas and primary fields of the neocortex. The basic concept is diagramed in Figure 1 .
B. Biomarkers for Parkinson's Disease and Parkinson's Disease Progression
Two approaches, protein-specific, for example, a-synuclein (Jakowec et al., 1998; Borghi et al., 2000; Verbeek, De Jong, & Kremer, 2003; El-Agnaf et al., 2006; Tokuda et al., 2006) and DJ-1 (Waragai et al., 2006; Hirotani et al., 2008) , and unbiased profiling (Abdi et al., 2006) have been undertaken to define protein biomarkers unique to PD diagnosis. Profiling is advantageous because it provides an unbiased view of a disease or stage of a disease whose pathogenesis is largely unknown. In addition, multiple markers can be generated for a given disease when a profiling approach is taken, and generally speaking, a combination of multiple markers offers better sensitivity and specificity than a single protein alone for disease diagnosis . There are no known markers that can predict PD progression, whether related to motor symptoms or cognitive impairment; that concept has been emphasized more recently. To resolve this issue, in the last few years, with unbiased proteomics, we have compared the proteome of brain tissue associated with Lewy body progression as PD advances, with the goal of identifying proteins before Lewy body formation in the neocortex (Fig. 1) . However, in an earlier analysis, among $1,500 proteins identified in CSF only 9% were present in the proteins identified in human brain tissue (Pan et al., 2007a,b) . It has been hypothesized that there are at least two limitations associated with the previous approaches: (1) the cellular fractionation technique is biased against extracellular proteins, because most of them are discarded along with cell debris Pan et al., 2007a) , and (2) the large dynamic range of the CSF proteome makes it very challenging to identify proteins of low abundance [albumin and immunoglobulins constitute more than 75% of CSF proteins (Srivastava, Murphy, & Jeffery, 2008) ]. Indeed, both limitations are the major problems that must be dealt with not only in diseases related to the CNS but also in the biomarker discovery field in general Qian et al., 2006) . To increase the likelihood of identifying proteins that are accessible clinically, most investigators have turned their attention either to removing high-abundance proteins before profiling or to a specific sub-proteome with a unique PTM; for example, proteins with glycosylation. As mentioned earlier, protein glycosylation, and in particular N-linked glycosylation, is prevalent in proteins destined for extracellular environments (Roth, 2002) .
C. Glycoprotein/Peptide in Human Cerebrospinal
Fluid and Brain Tissue
Glycoproteins in Human Cerebrospinal Fluid
This investigation consisted of four groups: control subjects, AD, and PD patients at two different stages. More specifically, the control group consisted of 29 individuals aged 70 AE 6 years, 18 men and 11 women, with no history, symptoms, or signs of psychiatric or neurological disease. The AD group consisted of 51 patients aged 69 AE 9 years, 28 men and 23 women, all of whom underwent a comprehensive clinical examination, and were diagnosed with AD according to NINCDS ADRDA criteria (Jobst, Barnetson, & Shepstone, 1997) . The early stage PD group consisted of 11 patients aged 61 AE 8 years, 9 men and 2 women, all of whom underwent a comprehensive clinical examination and were diagnosed with PD at a Hoehn and Yahr stage of 1.5 or less. The late stage PD group consisted of 11 patients aged 66 AE 7 years, 7 men and 4 women, all of whom underwent a comprehensive clinical examination and were diagnosed with PD at a Hoehn and Yahr stage of 3 or greater. All CSF samples have been controlled for blood contamination before pooling samples into four groups (Abdi et al., 2006) . The pooled CSF samples were mixed with a protease inhibitor cocktail, and stored at À808C before use. To perform quantitative analysis of glycoproteins unique to PD and PD progression, samples were digested with trypsin, followed with iTRAQ labeling, before hydrazide bead capture. Of note, quantitative data are still being evaluated currently and will be published separately at a later time. The glycopeptides derived from glycoproteins in human CSF were FIGURE 1. Cognitive impairment associated with PD progression is characterized pathologically by the spreading of a-synuclein aggregates, the main component of Lewy bodies, from brainstem to limbic system and eventually to the neocortex (Braak et al., 2003) . The boxed area, the middle frontal gyrus, is the tissue source for a recent non-biased profiling (Pan et al., 2007a; Shi et al., 2008) as well as characterization of glycoproteins to reveal proteins unique to PD and/or PD progression, particularly development of dementia.
[Color figure can be viewed in the online issue, which is available at www.interscience. wiley.com.] enriched by hydrazide bead capture followed by enzymatic release of the N-linked glycosylated peptides. Peptides from each sample were dissolved in 0.5% trifluoroacetic acid (TFA), and separated with reverse phase (RP) chromatography. MS/MS analysis used the 4800 Proteomics Analyzer with TOF/TOF Optics TM (Applied Biosystems, Foster City, CA, USA). The MS/ MS spectra were extracted and searched against the International Protein Index (IPI) human protein database (version 3.42 from the European Bioinformatics Institute [EBI]) with ProteinPilot TM software (version 2.0.1, revision 33087, Applied Biosystems) with the Paragon TM method. The raw peptide identification results from the Paragon TM Algorithm (Applied Biosystems) searches were further processed with the Pro Group TM Algorithm (Applied Biosystems) within the ProteinPilot TM software before final display. The Pro Group Algorithm uses the peptide identification results to determine the minimal set of proteins that can be reported for a given protein confidence threshold. For each protein, Pro Group Algorithm reports two types of scores for each protein: unused ProtScore and total ProtScore. The total ProtScore is a measurement of all the peptide evidence for a protein, and is analogous to protein scores reported by other protein identification software. The unused ProtScore, however, is a measurement of all the peptide evidence for a protein that is not better explained by a higher ranking protein. In other words, the unused ProtScore is calculated with the unique peptides (peptides that are not used by the higher ranking protein), and it is a clearer indicator of protein evidence and assists in singling out members of a multiprotein family. All reported data were based on 95% confidence for protein identification as determined by ProteinPilot (ProtScore !1.3). Identified glycoproteins were checked against the UniProtKB/Swiss-Prot database and the Institute for Systems Biology (ISB) database as glycoproteins with known glycosylation sites or probable/potential glycosylation sites.
The MALDI-TOF-TOF analysis revealed a total of 283 nonredundant glycoproteins in human CSF (Appendix I). In comparison with the existing publicly accessible database, 243 of these proteins were annotated in UniProtKB/Swiss-Prot and the ISB database as glycoproteins with known glycosylation sites or probable/potential glycosylation sites. The specificity of this approach was approximately 86% (243/283). When this dataset is compared with what has been published earlier, where lectin affinity purification and hydrazide chemistry were both used to characterize CSF glycoproteins with an ion trap mass spectrometer (LCQ) , 87 were observed in both datasets; that is, a 36% overlap of 243 glycoproteins. This overlap is considered reasonable, given that a different database and different technology (LCQ vs. MALDI-TOF-TOF as well as hydrazide chemistry þ lectin affinity vs. hydrazide chemistry alone) were used to characterize glycoproteins in two different studies.
Glycoproteins in Brain Tissue
An alternative approach to increase the chances to identify proteins of low abundance is to perform targeted proteomics; that is, identify proteins unique to a disease or disease progression in tissue, followed by confirmation and validation in a body fluid. This concept will be discussed further in a later section (targeted proteomics). To characterize tissue glycoproteins associated with PD and PD progression, particularly those related to development of PD dementia, the advantage of well-characterized PD brains obtained at autopsy was taken. In this study, all PD cases had been given a clinical diagnosis of PD initially, which meant that dementia with Lewy body disease (DLB) cases, a disease overlapping with PD with dementia (PDD) cases pathologically, were excluded from the study. The brain region of interest was the middle frontal gyrus (Fig. 1) , and the four groups of cases (five per group with matching age, gender, and post-mortem interval) were investigated: normal age-matched control (78.6 AE 4.0; male/female [M/F] ratio ¼ 3:2), PD with brainstem Lewy bodies only (77.2 AE 11.3; M/F ¼ 3:2), PD with brainstem and limbic Lewy bodies (78.8 AE 8.3; M/F ¼ 3:2), and PD with Lewy bodies in neocortex plus brainstem and limbic system (77.0 AE 1.9; M/ F ¼ 3:2). Glycoproteins were isolated with methods identical to those described for CSF above after iTRAQ labeling. Again, the quantitative data will be published in a separate manuscript that is under preparation.
This investigation revealed 394 non-redundant glycoproteins (Appendix II). In comparison with the existing database, 343 of these proteins were annotated in the UniProtKB/SwissProt and ISB databases as glycoproteins with known glycosylation sites or probable/potential glycosylation sites. The specificity was approximately 87% (343/394). It should be emphasized that this dataset represents the first systematic analysis of glycoproteins in human brain in normal and diseased settings.
Gene Ontology Analysis
Over the last few years, a Gene Ontology (GO) method has been used to study datasets generated by proteomic analysis (Pan et al., 2007a,b; Kitsou et al., 2008; Shi et al., 2008) to provide insight into the underlying biology (Alexa, Rahnenfuhrer, & Lengauer, 2006) . GO analysis, either based on cellular components (CC) or biological processes (BP), detects over-represented GO categories (Alexa, Rahnenfuhrer, & Lengauer, 2006) . When the glycoproteins identified in human CSF and tissues were classified by GO analysis, it was apparent that a majority of the proteins belong to either the extracellular compartment or are associated with the plasma membrane (Fig. 2) . This is entirely consistent with the claim that most membrane proteins are glycosylated, and that a significant portion of glycoproteins are designated for secretion into the extracellular fluid and thereby enter blood or CSF (Yang et al., 2005) .
A Brief Discussion of Overlapped Proteins
As indicated earlier, one of the major goals to isolate glycoproteins is to reveal CNS-specific proteins that are low in abundance in body fluids with the potential to serve as biomarkers for disease diagnosis or disease progression. To this end, there are a few features of the data presented above that must be stressed: (1) isolation of glycoproteins significantly increased the portion of proteins related to CNS function and/or structure (a partial list of those proteins is shown in Table 1 ), (2) the overlap between the CSF and tissue proteomes is also improved significantly over the general profiling, where only 140 proteins were found in tissue and CSF general profiles that account for 9% of $1,500 identified CSF proteins. When glycoproteins were analyzed, 98 proteins were seen in brain tissue (a total of 343 proteins) and CSF (a total of 243 proteins) to account for 43% of CSF glycoproteins. Furthermore, several of the overlapping proteins identified with glycoprotein isolation are likely related to PD pathogenesis. For example, ceruloplasmin and transferrin, both regulate iron metabolism, were reported to be dysregulated in PD patients (Dexter et al., 1989; Riederer et al., 1989) .
Besides the proteins known to be important to PD pathogenesis, others such as neuroserpin, neural cell adhesion molecule, and neuronal pentraxin II are critical to CNS function, and some have been linked to other neurodegenerative diseases. For example, one of the overlapping proteins, neuroserpin, is a member of the serpin family of serine protease inhibitors. Tissuedistribution analysis reveals a predominantly neuronal expression during the late stages of neurogenesis and, in the adult brain, FIGURE 2. GO analysis of glycoproteins identified in human brain (A) and CSF (B), to clearly emphasize the fact that a majority of the proteins are distributed to extracellular and membrane compartments. in areas where synaptic changes are associated with learning and memory (synaptic plasticity). To this end, it should be mentioned that synaptic dysfunction appears to be one of the major early signs of PD progression in human cortex (Pisani et al., 2005) .
GLYCOPROTEOMICS IN NEURODEGENERATIVE DISEASES &
Another example, neural cell adhesion molecule, is involved in signal transduction (Niethammer et al., 2002) , and promotes neurite outgrowth and fasciculation (Rutishauser & Edelman, 1980) . In the SNpc of PD patients, polysialated-neural cell-adhesion molecule-positive immature neurons were detected. The polysialated neural cell adhesion molecule is a marker of immature, migrating neuroblasts (Yoshimi et al., 2005) . The third example, neuronal pentraxin II, was recently reported to be highly up-regulated in PD and is a novel component of Lewy bodies (Moran et al., 2008) . Neuronal pentraxin II is also known as the neuronal activity-regulated protein, which is secreted and involved in long-term neuronal plasticity (Hsu & Perin, 1995) .
V. FUTURE PERSPECTIVES
From the analysis of glycoproteins of human CSF and brain tissue, it is obvious that even a focused analysis of glycoproteins remains inadequate for an extensive characterization of CNSspecific proteins. When comparing glycoproteins identified in brain tissue (Appendix II) with those identified in CSF (Appendix I), we found, as expected, that proteins related to the CNS structurally and/or functionally are more frequently identified/ quantified in tissue. Because of dynamic issues and a common technical caveat associated with MS-based proteomics, absence of a protein only means that it is not detected, but not necessarily absent, in a particular analysis. We believe that it is critical to examine the tissue proteins unique to a disease process (PD diagnosis and progression in this case) in body fluid by targeted analysis. In our opinion, this approach is critical to the CNSbased disease, given that the CNS is highly organized and specialized with each neurodegenerative disorder that involves selective brain regions. For example, AD predominantly affects the cerebral cortex and hippocampus, whereas PD usually damages brainstem structures, particularly during the early stages of the diseases before other brain regions are involved (Braak et al., 2000; Wenk, 2003; Sudo et al., 2005) . Therefore, the pathology-specific proteins could be so diluted in CSF that they are difficult to detect even when glycoproteins are isolated first.
Targeted analysis of proteomics-first identify unique proteins in the CNS, followed by confirmation/validation of known proteins in CSF or plasma in this case-indicates a progression away from unbiased profiling toward a multi-phase technology that allows key elements that uniquely represent a specific biological condition to be analyzed (Aebersold, 2003; Pan et al., 2005) . The technology uses isotope dilution followed by MS analysis (Gerber et al., 2003; Anderson et al., 2004; Anderson, 2005; Pan et al., 2005; Anderson & Hunter, 2006) , in which test-samples are supplemented (spiked) with synthetic peptides that serve as the signature markers to identify and quantify native peptides (target) within each sample. To date, few investigations have been reported that use the concept of candidate-based targeted quantitative proteomics to study selected peptides/proteins for biomarker verification/validation via ESI or MALDI based platforms. For the ESI approach, a hybrid triple-quadrupole/ion trap mass spectrometer was used to identify and quantify a selected group of targeted proteins within human plasma (Anderson & Hunter, 2006) . Alternatively, an off-line LC MALDI-TOF/TOF platform was established to monitor a panel of targeted glycopeptides/glycoproteins in human serum, in conjunction with a sample preparation strategy that extracted deglycosylated N-linked glycopeptides from human serum (Pan et al., 2005) . These early investigations have demonstrated the feasibility and advantages of the MS-based targeted quantitative proteomics to simultaneously identify and quantify a panel of selected peptides/proteins in a complex milieu, and consequently could be applied for biomarker verification/validation of AD and PD. Figure 3 demonstrates the basic concepts and work flow to validate a protein of interest in an LC-MALDI format. In fact, we have recently applied this technology to confirm/validate a subset of proteins identified in a previous non-biased proteomics profiling (Abdi et al., 2006) unique to AD and PD, respectively, in CSF . A project is also underway to use this platform to cross-examine the proteins identified in brain tissue with CSF (and vice versa), and eventually in human plasma.
VI. CONCLUDING REMARKS
The development of technologies from gel electrophoresisbased approaches to high-resolution MS-based approaches for protein identification and quantification has revolutionized protein biomarker discovery critical to disease diagnosis and disease progression monitoring, as well as greatly facilitated studies to reveal the molecular events that underlie neurodegenerative diseases. Among these studies, protein glycosylation and glycoproteomics are growing fields of interest due to the relationship between glycosylation degree/type and the health status of cells. The discovery and identification of glycosylated peptides and proteins and the analyses of their glyco-structures are increasingly important in diagnosis and treatment of neurodegenerative diseases. However, it is obvious that the complete characterization of glycoproteins remains a major challenge in the years to come, largely because of the enormous dynamic range of typical human samples as well as the heterogeneity of human beings. Thus, effective and in-depth protein identification of glycoproteins involved in neurodegenerative disorders requires a concerted approach, including improved glycoprotein enrichment, extensive separation of proteins/peptides, high-resolution tandem mass spectrometric analysis, at profiling and targeted modes, and state-of-the-art bioinformatics.
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VII. APPENDIX I: GLYCOPEPTIDES IDENTIFIED IN HUMAN CEREBROSPINAL FLUID
